JALUPRO® Young Eye (1 x 1.0 mL) | Professional Derma SA

Short Description

A specialized periorbital biorevitalizer formulated specifically for the delicate eye contour. Combining Bi-Density Non-Cross-Linked Hyaluronic Acid, a concentrated 7-Amino-Acid functional cluster, and 3 targeted biomimetic peptides (Acetyl Decapeptide-3, Oligopeptide-24, and Acetyl Tetrapeptide-5), JALUPRO® Young Eye targets tear trough hollows, dark circles, lymphatic under-eye puffiness, and crow’s feet rhytids—rebuilding dermal thickness, improving periorbital microcirculation, and smoothing crepey skin without hydrophilic malar edema or Tyndall effect.

Detailed Description

JALUPRO® Young Eye is a sterile, non-pyrogenic, absorbable physiological injectable solution developed by Professional Derma SA (Switzerland / Italy). While traditional hyaluronic acid fillers in the infraorbital zone carry known risks of the Tyndall effect, lymphatic blockage, and persistent hydrophilic swelling, Jalupro Young Eye is calibrated to address the root histological causes of periorbital aging: extreme dermal thinning, loss of collagen/elastin scaffolding, impaired microvascular drainage, and orbital retaining ligament descent.

The formulation operates through a complementary tripartite bio-complex:

1. Bi-Density Non-Cross-Linked Hyaluronic Acid: Utilizes two distinct molecular weights of pure physiological sodium hyaluronate with calibrated rheological fluidity. This bi-density matrix provides immediate extracellular hydration and osmotic balance without drawing excessive water into the non-distensible infraorbital space, minimizing the risk of post-procedure edema.

2. The 7-Amino-Acid Structural Cluster: Delivers high concentrations of Glycine, L-Proline, L-Leucine, L-Lysine HCl, L-Alanine, L-Valine, and L-Arginine HCl. This specific stoichiometric ratio provides the essential substrate pool needed by periorbital fibroblasts to synthesize Pro-Collagen alpha chains, accelerating de novo deposition of Type I and Type III collagen to visibly thicken the translucent skin barrier.

3. Targeted Periorbital Peptide Complex (3 Biomimetic Peptides):

   • Acetyl Tetrapeptide-5: Inhibits glycation of vascular proteins, reduces microvascular permeability, and promotes lymphatic drainage to alleviate fluid pooling, bags, and bluish vascular dark circles.

   • Acetyl Decapeptide-3: Mimics natural growth factor signaling, stimulating cellular proliferation and extracellular matrix (ECM) repair to rebuild tissue elasticity.

   • Oligopeptide-24: Upregulates cellular transcription of endogenous collagen and elastin while dampening micro-muscular skin tension around dynamic expression lines.

Treatment Areas & Indications

• Infraorbital Tear Trough & Palpebromalar Groove:

  • Mild-to-moderate tear trough depression without significant herniated fat pads

  • Blending the transition between the lower eyelid and the cheek complex

• Periorbital Dyschromia (Dark Circles):

  • Vascular Dark Circles: Bluish/purplish coloration caused by visible sub-dermal capillaries showing through thinned eyelid skin

  • Pigmentary & Dehydration Shadowing: Sunken, tired hollows accentuating structural orbital shadowing

• Lower Eyelid & Canthal Skin Laxity:

  • Crepey, fragile, and paper-thin skin of the lower periorbital envelope

  • Dynamic and static lateral canthal lines (crow’s feet)

• Lymphatic Stagnation & Under-Eye Puffiness:

  • Early-stage fluid retention and morning puffiness secondary to poor periorbital microcirculation

Key Clinical Advantages

• Engineered Against Malar Edema: Formulated with non-cross-linked HA and lymphatic-draining peptides, eliminating the long-term water-retentive pockets and festoons frequently caused by cross-linked BDDE gel fillers.

• Zero Tyndall Effect: Completely transparent, low-viscosity fluid that integrates into the tissue without creating bluish surface discoloration even when placed in close proximity to thin cutaneous layers.

• Dual Action (Thickening + Decongesting): Simultaneously thickens the skin barrier (concealing underlying vessels) while stimulating microvascular and lymphatic flow to clear pigmentary and fluid stagnation.

• Minimal Downtime & Rapid Recovery: Needle marks or small micro-papules generally resolve within 24 to 48 hours, allowing patients to resume normal routines quickly.

• Cannula- and Needle-Versatile: Can be administered via direct micro-papular needle injection or single-puncture blunt microcannula fan vectoring.

Recommended Clinical Protocols & Delivery Techniques

Technique	Recommended Instrument	Injection Plane	Administration Method
Blunt Microcannula (Preferred)	27G or 30G x 25–38 mm blunt cannula	Deep subcutaneous / Pre-periosteal plane	Single lateral entry point at the zygomatic border; retrograde linear fanning of 0.3–0.5 mL per side under the orbicularis oculi muscle
Micro-Papular Needle Technique	32G or 34G x 4 mm micro-needle	Deep reticular dermis / Subdermal junction	Micro-boluses of 0.01–0.02 mL per point, spaced 3–5 mm apart along the infraorbital rim and lateral crow’s feet

• Standard Treatment Schedule: 3 to 4 sessions spaced 2 to 3 weeks apart.

• Maintenance Protocol: 1 session every 4 to 6 months to maintain periorbital dermal density.

Technical Specifications

Parameter	Specification
Product Classification	Periorbital Biorevitalizer / Class III Medical Device
Manufacturer / Origin	Professional Derma SA (Lugano, Switzerland / Italy)
Hyaluronic Acid Profile	Bi-density non-cross-linked sodium hyaluronate (BDDE-free)
Amino Acid Complex (7 AAs)	Glycine, L-Proline, L-Leucine, L-Lysine HCl, L-Alanine, L-Valine, L-Arginine HCl
Biomimetic Peptides (3 Peptides)	Acetyl Decapeptide-3, Oligopeptide-24, Acetyl Tetrapeptide-5
Packaging Presentation	1 x 1.0 mL pre-filled sterile glass syringe
Lidocaine Content	Lidocaine-free (compatible with topical lidocaine cream pre-treatment)
Target Injection Planes	Deep reticular dermis, sub-orbicularis plane, or supraperiosteal margin
Recommended Application Tools	30G (25 mm) blunt cannula or 32G (4 mm) micro-meso needle
Expected Clinical Duration	6 to 9 months (up to 12 months with maintenance)
Storage Instructions	Store between 2°C and 25°C (36°F to 77°F); protect from light and freezing
Regulatory Category	CE-marked Class III Medical Device / Prescription Only (Rx)

The Jalupro® Injectable Family Comparison

Product	Presentation	Primary Active Focus	Key Clinical Indication
Jalupro Classic	2 vials (dry AAs) + 2 ampoules (HA)	30 mg HA + 4 Amino Acids	Superficial photoaging, fine lines, full face
Jalupro HMW	1 x 1.5 mL syringe + 1 mL AA vial	20 mg/mL High-MW HA + 4 Amino Acids	Deep dermal folds, neck, hands, severe dehydration
Jalupro Super Hydro	1 x 2.5 mL syringe	80 mg Hybrid HA + 7 AAs + 3 Peptides	Facial retaining ligaments (LBD), vector lifting, lower face
Jalupro Young Eye	1 x 1.0 mL syringe	Bi-Density HA + 7 AAs + 3 Peptides	Periorbital zone, tear troughs, dark circles, eye bags

Professional Advisory: JALUPRO® Young Eye is intended strictly for certified aesthetic physicians, dermatologists, and plastic surgeons trained in periorbital anatomy, the course of the angular and infraorbital vessels, and blunt microcannula placement. Direct intra-arterial or intravenous injection, as well as superficial boluses inside active herniated fat pads (steatoblepharon), is strictly contraindicated.